Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metabolism

Background:

• Activating BRAF mutations, common in cutaneous melanoma (up to 50%), drive glycolysis for proliferation.
• BRAF mutations, particularly V600E, historically correlated with aggressive metastatic disease.
• Targeted BRAF and MEK inhibition is a first-line treatment for advanced melanoma but often leads to resistance.

Purpose of the Study:

• To describe metabolic pathways modulated by BRAF inhibition in melanoma.
• To identify adaptive metabolic vulnerabilities in BRAF-mutated melanoma.
• To evaluate therapeutic strategies targeting metabolic reprogramming to overcome resistance.

Main Methods:

• Review of core metabolic pathways affected by BRAF inhibition in melanoma.
• Analysis of metabolic rewiring in response to targeted anti-BRAF therapies.
• Evaluation of current and future therapeutic strategies targeting metabolic vulnerabilities.

Main Results:

• BRAF inhibition shifts melanoma cell metabolism from glycolysis to mitochondrial oxidative phosphorylation.
• Melanoma cells upregulate the TCA cycle and increase glutamine utilization to support this metabolic shift.
• These adaptive metabolic changes represent potential vulnerabilities for therapeutic intervention.

Conclusions:

• Targeted BRAF inhibition induces significant metabolic reprogramming in melanoma cells.
• Increased reliance on glutamine and mitochondrial metabolism presents vulnerabilities.
• Targeting these metabolic adaptations offers a promising strategy to overcome resistance to BRAF inhibitors.